Growing ophthalmology Tilak Healthcare's OdySight is a CE-marked medical device and the first of its kind to monitor vision remotely, already prescribed to thousands of patients primarily in France, signaling a receptive market for digital ophthalmology tools and remote patient monitoring.

Strategic partnerships Past and ongoing partnerships with Novartis and international distributors (Novartis Schweiz, distribution deals) indicate strong access points for expansion and co-development opportunities in other regions, including the US and Europe.

Funded growth With multiple funding rounds totaling around €21 million and recent 2023 investment of approximately €10 million, Tilak has capital to scale sales efforts, expand market penetration, and support clinical validation campaigns.

Clinical adoption The product has real-world clinical traction, prescribed to 15,000 patients since 2018, and is integrated with national healthcare systems, suggesting a compelling value proposition for payers, clinics, and hospital networks seeking digital monitoring solutions.

Global expansion OdySight is available in five languages and marketed in France, Spain, Belgium, and the US, indicating an opportunity to accelerate regional deployments with tailored regulatory, reimbursement, and localization strategies.